BALISTANCT06793332
BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC
At risk: Primary completion moved 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jan 31, 2026 to Dec 31, 2026 Show 5 more changesShow less
- Start date: Dec 17, 2024 to Feb 5, 2025
- Eligibility criteria expanded, about 21 words
- Study completion pushed from Jan 31, 2027 to May 31, 2027
- Secondary endpoints: details revised at 3 of 3 entries
- Publications: details revised at 4 of 4 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Intracranial objective response rate (CNS ORR)
Timeframe: 22 months(Up to approximately 12 weeks after the last patient's enrollment)
Secondary (3)
Intracranial clinical benefit rate (CNS CBR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Arms and interventions
Ivonescimab combined with TROP2 ADCExperimental
Drugs: Ivonescimab Combined With TROP2 ADC
Sites
1 site in 1 country
- Fudan University Shanghai Cancer centerShanghai, Shanghai Municipality, China